Overview Dividends

(IRWD) Ironwood Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46333X1081

Linaclotide, Apraglutide, IW-3300

Biotechnology
Market Cap in USD: 530m

IPO / Inception: 2010-02-03
Return 12m vs S&P 500: -40.3%

EPS (Earnings per Share)

EPS CAGR: -3.09%
EPS Trend: -58.5%

Last SUE: 0.99
Qual. Beats: 2

Revenue

Rev. CAGR: 1.11%
Rev. Trend: -39.9%

Last SUE: 2.89
Qual. Beats: 2

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	115%
Value at Risk 5%th	161%
Relative Tail Risk	-14.80%

Reward TTM
Sharpe Ratio	0.28
Alpha	-36.15
CAGR/Max DD	-0.37

Character TTM
Hurst Exponent	0.494
Beta	0.982
Beta Downside	1.229

Drawdowns 3y
Max DD	96.33%
Mean DD	52.55%
Median DD	58.12%

Description: IRWD Ironwood Pharmaceuticals November 15, 2025

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a Boston-based biotech that develops and markets gastrointestinal (GI) and rare-disease therapies, most notably the GC-C agonist linaclotide sold as LINZESS (adult IBS-C/CC) and CONSTELLA (pediatric functional constipation).

In 2023 linaclotide generated approximately $1.1 billion in net sales, representing roughly 30 % of Ironwood’s total revenue and giving the company a leading share in the U.S. prescription constipation market, which analysts estimate will grow at a 5-6 % CAGR through 2029.

The pipeline includes IW-3300, a next-generation GC-C agonist targeting visceral-pain disorders such as interstitial cystitis/bladder pain syndrome and endometriosis, and Apraglutide, a long-acting GLP-2 analog being evaluated for short-bowel syndrome patients dependent on parenteral nutrition and for acute graft-versus-host disease.

Ironwood has entered commercialization and development alliances with AbbVie, AstraZeneca, and Astellas, which provide co-promotion capabilities and share development risk; these partnerships are a key driver of cash efficiency, allowing the company to maintain a cash runway of roughly $400 million at the end of Q2 2024.

Sector-wide, biotech firms benefit from a favorable capital environment (average 2024 biotech IPO proceeds ≈ $600 million) and rising demand for specialty GI drugs, but they also face pricing pressure from insurers and the need to demonstrate differentiated efficacy in late-stage trials.

For a deeper, data-driven look at Ironwood’s valuation metrics and scenario analysis, you may find the research tools on ValueRay useful for extending this initial overview.

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (28.5m TTM) > 0 and > 6% of Revenue (6% = 20.3m TTM)

FCFTA 0.17 (>2.0%) and ΔFCFTA -14.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 9.25% (prev 34.15%; Δ -24.90pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.17 (>3.0%) and CFO 67.7m > Net Income 28.5m (YES >=105%, WARN >=100%)

Net Debt (457.8m) to EBITDA (146.9m) ratio: 3.12 <= 3.0 (WARN <= 3.5)

Current Ratio 1.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (177.8m) change vs 12m ago 10.94% (target <= -2.0% for YES)

Gross Margin 68.62% (prev 85.03%; Δ -16.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 86.30% (prev 97.15%; Δ -10.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 4.29 (EBITDA TTM 146.9m / Interest Expense TTM 33.8m) >= 6 (WARN >= 3)

Altman Z'' -13.42

(A) 0.08 = (Total Current Assets 273.8m - Total Current Liabilities 242.5m) / Total Assets 396.1m

(B) -4.22 = Retained Earnings (Balance) -1.67b / Total Assets 396.1m

warn (B) unusual magnitude: -4.22 — check mapping/units

(D) -2.53 = Book Value of Equity -1.67b / Total Liabilities 660.2m

Total Rating: -13.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 58.00

1. Piotroski 4.0pt

2. FCF Yield 6.85%

3. FCF Margin 19.96%

4. Debt/Equity -2.26

5. Debt/Ebitda 3.12

6. ROIC - WACC (= 25.30)%

7. RoE -9.46%

8. Rev. Trend -39.91%

9. EPS Trend -58.47%

What is the price of IRWD shares?

As of December 24, 2025, the stock is trading at USD 3.21 with a total of 976,730 shares traded.
Over the past week, the price has changed by -9.32%, over one month by -3.31%, over three months by +130.94% and over the past year by -30.07%.

Is IRWD a buy, sell or hold?

Ironwood Pharmaceuticals has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold IRWD.

Strong Buy: 0
Buy: 0
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the IRWD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	2.5	-22.1%
Analysts Target Price	2.5	-22.1%
ValueRay Target Price	2.9	-9%

IRWD Fundamental Data Overview December 20, 2025

Market Cap USD = 530.3m (530.3m USD * 1.0 USD.USD)
P/E Trailing = 18.1111
P/E Forward = 12.3305
P/S = 1.5645
P/B = 2.5899
P/EG = -0.26
Beta = 0.18
Revenue TTM = 339.0m USD
EBIT TTM = 145.0m USD
EBITDA TTM = 146.9m USD
Long Term Debt = 385.0m USD (from longTermDebt, last quarter)
Short Term Debt = 202.7m USD (from shortTermDebt, last quarter)
Debt = 598.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 457.8m USD (from netDebt column, last quarter)
Enterprise Value = 988.2m USD (530.3m + Debt 598.2m - CCE 140.4m)
Interest Coverage Ratio = 4.29 (Ebit TTM 145.0m / Interest Expense TTM 33.8m)
FCF Yield = 6.85% (FCF TTM 67.6m / Enterprise Value 988.2m)
FCF Margin = 19.96% (FCF TTM 67.6m / Revenue TTM 339.0m)
Net Margin = 8.42% (Net Income TTM 28.5m / Revenue TTM 339.0m)
Gross Margin = 68.62% ((Revenue TTM 339.0m - Cost of Revenue TTM 106.4m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 99.45%)
Tobins Q-Ratio = 2.49 (Enterprise Value 988.2m / Total Assets 396.1m)
Interest Expense / Debt = 1.41% (Interest Expense 8.43m / Debt 598.2m)
Taxrate = 41.08% (27.9m / 68.0m)
NOPAT = 85.4m (EBIT 145.0m * (1 - 41.08%))
Current Ratio = 1.13 (Total Current Assets 273.8m / Total Current Liabilities 242.5m)
Debt / Equity = -2.26 (negative equity) (Debt 598.2m / totalStockholderEquity, last quarter -264.2m)
Debt / EBITDA = 3.12 (Net Debt 457.8m / EBITDA 146.9m)
Debt / FCF = 6.77 (Net Debt 457.8m / FCF TTM 67.6m)
Total Stockholder Equity = -301.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.21% (Net Income 28.5m / Total Assets 396.1m)
RoE = -9.46% (negative equity) (Net Income TTM 28.5m / Total Stockholder Equity -301.9m)
RoCE = 174.5% (EBIT 145.0m / Capital Employed (Equity -301.9m + L.T.Debt 385.0m))
RoIC = 30.26% (NOPAT 85.4m / Invested Capital 282.3m)
WACC = 4.97% (E(530.3m)/V(1.13b) * Re(9.63%) + D(598.2m)/V(1.13b) * Rd(1.41%) * (1-Tc(0.41)))
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.74%
[DCF Debug] Terminal Value 63.64% ; FCFE base≈90.1m ; Y1≈59.2m ; Y5≈27.1m
Fair Price DCF = 2.56 (DCF Value 417.1m / Shares Outstanding 162.7m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -58.47 | EPS CAGR: -3.09% | SUE: 0.99 | # QB: 2
Revenue Correlation: -39.91 | Revenue CAGR: 1.11% | SUE: 2.89 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.02 | Chg30d=+0.035 | Revisions Net=+2 | Analysts=2
EPS next Year (2026-12-31): EPS=0.46 | Chg30d=+0.247 | Revisions Net=+2 | Growth EPS=+55.9% | Growth Revenue=+4.1%

Additional Sources for IRWD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle